Pomaglumetad methionil is under clinical development by Denovo Biopharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pomaglumetad methionil’s likelihood of approval (LoA) and phase transition for Drug Addiction took place on 10 Oct 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pomaglumetad methionil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pomaglumetad methionil overview

Pomaglumetad methionil (DB103, LY-2140023) is under development for the treatment of schizophrenia and methamphetamine addiction. It is a new chemical entity (NCE), administered orally. The drug candidate targets metabotropic glutamate receptor (mGluR)2 and mGluR3. The drug candidate is a methionine amide prodrug. LY-2140023 is metabolized to the active receptor agonist LY-404039 which modulates the presynaptic release of glutamate in those regions of the brain where mGlu2/3 receptors are expressed.

Denovo Biopharma overview

Denovo Biopharma, formerly Denovo Biomarkers is a biotechnology company that provides novel biomarker solutions to personalize drug development. The company enables drug developers to design new clinical trials in targeted patient populations and re-evaluates medicines that failed in general patient populations. Its core technology performs genomic biomarker discovery using archived clinical samples. Denovo Biopharma supports its partners throughout the evolution process up to the approval and launch of the drug together with the companion diagnostic test. The company also partners with life science companies and drug developers. It has operations in the US and China. Denovo Biopharma is headquartered in San Diego, California, the US.

Quick View Pomaglumetad methionil LOA Data

Report Segments
  • Innovator
Drug Name
  • Pomaglumetad methionil
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.